Verification evidence is still being completed.
PDF / print export
Zelluna ASA
Oslo, Norway
- Verified lead
- Namir Hassan
- Lead status
- STATUS: VERIFIED APRIL 2026
- Leadership verification
- Chief Executive Officer
- 2026 technical specialization
- Off-the-Shelf TCR-NK Cell Therapy, Solid Tumor Oncology, and MAGE-A4 Lead Program
- Review cycle
- 24 April 2026
- Full address
- Ullernchausseen 64, 0379 Oslo, Norway
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Zelluna ASA management page listing Namir Hassan as Chief Executive Officer.
- Editorial note
- Norway's first publicly listed cell-therapy company with named CEO, Euronext Oslo listing (ZLNA, March 2025), and a MAGE-A4 TCR-NK program advancing toward IND.
Off-the-Shelf TCR-NK Cell Therapy, Solid Tumor Oncology, and MAGE-A4 Lead Program
Euronext Oslo listing disclosure, OCC Innovation Park tenancy, OUS TRU NK-TCR license
Norway's first publicly listed cell-therapy company with named CEO, Euronext Oslo listing (ZLNA, March 2025), and a MAGE-A4 TCR-NK program advancing toward IND.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Oslo, Norway
Zelluna ASA
Off-the-Shelf TCR-NK Cell Therapy, Solid Tumor Oncology, and MAGE-A4 Lead Program · Clinical-stage cell therapy development
Norway's first publicly listed cell-therapy company with named CEO, Euronext Oslo listing (ZLNA, March 2025), and a MAGE-A4 TCR-NK program advancing toward IND.
- Lead
- Namir Hassan (verified ↗)
- Address
- Ullernchausseen 64, 0379 Oslo, Norway (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 24 Apr 2026 (1mo ago)
- Scale
- Clinical-stage cell therapy development
- Capabilities
- TCR-NK Allogeneic Cell Therapy Platform · MAGE-A4 TCR Lead Program · UV1 Peptide Cancer Vaccine (Legacy Asset)
- Founded
- 2016
- Headcount
- 11-50
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED APRIL 2026
Namir Hassan
Chief Executive Officer
Full addressUllernchausseen 64, 0379 Oslo, Norway
Site coordinatesVerification evidence is still being completed.
Review cycle24 April 2026
Physical site source
Zelluna ASA official site listing Oslo Cancer Cluster Innovation Park (Ullernchausseen 64).
Open sourceClinical-stage cell therapy development
Oslo, Norway. Off-the-Shelf TCR-NK Cell Therapy, Solid Tumor Oncology, and MAGE-A4 Lead Program. Review completed on 24 Apr 2026.
Norwegian Medicines Agency and EMA for clinical development
Euronext Oslo listing disclosure, OCC Innovation Park tenancy, OUS TRU NK-TCR license
Off-the-Shelf TCR-NK Cell Therapy, Solid Tumor Oncology, and MAGE-A4 Lead Program
Norway's first publicly listed cell-therapy company with named CEO, Euronext Oslo listing (ZLNA, March 2025), and a MAGE-A4 TCR-NK program advancing toward IND.
Editorial note
Zelluna ASA is Norway's first publicly-listed cell-therapy company, formed from the combination of Ultimovacs (UV1 peptide vaccine legacy) and Zelluna Immunotherapy (TCR-NK platform), headquartered at the Oslo Cancer Cluster Innovation Park.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleApril 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
TCR-NK Allogeneic Cell Therapy Platform
MAGE-A4 TCR Lead Program
UV1 Peptide Cancer Vaccine (Legacy Asset)
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
TCR-NK cell therapy platform
Partner-led clinical manufacturing
OCC Innovation Park tenancy
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
24 Apr 2026: Executive identity confirmed via official management disclosure.
24 Apr 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Zelluna ASA located?
- Zelluna ASA operates from Ullernchausseen 64, 0379 Oslo, Norway, Oslo, Norway.
- Who runs Zelluna ASA?
- Zelluna ASA is led by Namir Hassan, Chief Executive Officer. Verified 24 Apr 2026.
- What does Zelluna ASA do?
- Norway's first publicly listed cell-therapy company with named CEO, Euronext Oslo listing (ZLNA, March 2025), and a MAGE-A4 TCR-NK program advancing toward IND. Core capabilities: TCR-NK Allogeneic Cell Therapy Platform, MAGE-A4 TCR Lead Program, UV1 Peptide Cancer Vaccine (Legacy Asset).
Editorial context
Related technical briefs
Briefs that name Oslo as a covered market or city.